The genetics of lupus

Current Opinion in Rheumatology

Volumn 10, Issue 5, 1998, Pages 399-408

  Tan, Filemon K ^a   Arnett, Frank C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT RECEPTOR; CYTOKINE; HLA DQ ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN RECEPTOR; MANNOSE BINDING PROTEIN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR;

APOPTOSIS; DNA POLYMORPHISM; ETHNOLOGY; GENE LOCUS; GENETICS; HLA SYSTEM; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; APOPTOSIS; CARRIER PROTEINS; HLA ANTIGENS; HUMANS; INTERLEUKINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MANNOSE-BINDING LECTINS; RECEPTORS, IGG; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031715856     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199809000-00002     Document Type: Review

References (86)

1. Arnett FC: The genetics of human lupus. In Dubois' Lupus Erythematosus. Edited by Wallace DR, Hahn BH. Baltimore: Williams & Wilkins; 1997:77-117.
2. Lawrence JS, Martins CL, Drake GL: A family survey of lupus erythematosus: 1. Heritability. J Rheumatol 1987, 14:913-921.
3. Risch N: Assessing the role of HLA-linked and unlinked determinants of disease. Am J Hum Genet 1987, 40:1-14.
4. Vyse TJ, Todd JA: Genetic analysis of autoimmune disease. Cell 1996, 85:311-318.
5. Block S, Winfield J, Lockshin M, D'Angelo W, Christian D: Studies of twins with systemic lupus erythematosus. Am J Med 1975, 59:533-552.
6. Grennan DM, Parfitt A, Manolios N, Huang Q, Hyland V, Dunckley H, Doran T, Gatenby P, Badcock C: Family and twin studies in systemic lupus erythematosus. Dis Markers 1997, 13:93-98. This study estimated how much of the total genetic predisposition to SLE can be attribute to HLA by comparing figures for concordance of SLE in monozygotic twins with those for concordance in HLA-identical sibs in Australia.
7. Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman P, Walter A, Mack T: Revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 1992, 35:311-318.
8. Freedman BI, Wilson CH, Spray BJ, Tuttle AB, Olorenshaw IM, Kammer GM: Familial clustering of end-stage renal disease in blacks with lupus nephritis. Am J Kidney Dis 1997, 29:729-732. This paper determined whether renal disease aggregated in select families or was a sporadic complication in patients with SLE. Familial clustering of ESRD was observed in black patients with SLE who had nephritis, suggesting there is an inherited susceptibility to renal failure independent of the cause of ESRD.
9. Nepom BS, Nepom GT: Polyglot and polymorphism. An HLA update. Arthritis Rheum 1995, 38:1715-1721.
10. Arnett FC, Reichlin M: Lupus hepatitis: an underrecognized disease feature associated with autoantibodies to ribosomal P. Am J Med 1995, 99:465-472.
11. Arnett FC, Reveille JD, Moutsopoulos H, Georgescu L, Elkon K: Ribosomal P antibodies in systemic lupus erythematosus. Arthritis Rheum 1996, 39:1833-1839.
12. Gharavi A, Wilson W: Antiphospholipid antibodies. In Dubois' Lupus Erythematosus. Edited by Wallace DR, Hahn BH. Baltimore: Williams & Wilkins; 1997:471-491.
13. McCarty-Farid G: The lupus anticoagulant and antiphospholipid antibodies. In Dubois' Lupus Erythematosus. Edited by Wallace DR, Hahn BH. Baltimore: Williams & Wilkins; 1997:493-504.
14. Granados J, Vargas-Alarcon G, Drenkard C, Andrade F, Melin-Aldana H, Alcocer-Varela J, Alarcon-Segovia D: Relationship of anticardiolipin antibodies and antiphospholipid syndrome to HLA DR7 in Mexican patients with systemic lupus erythematosus (SLE). Lupus 1996, 6:57-62. The authors found a significantly increased frequency of HLA-DR7 in SLE patients with antiphospholipid syndrome. Moreover, the distribution of HLA alleles in SLE patients resembles that found in their anticardiolipin antibody-positive first-degree relatives.
15. Hartung K, Coldewey R, Corvetta A, Deicher H, Kalden JR, Krapf F, Lang B, et al.: MHC gene products and anticardiolipin antibodies in systemic lupus erythematosus: results of a multicenter study. SLE study group. Autoimmunity 1992, 13:95-99.
16. Goldstein R, Moulds JM, Smith CD, Sengar DP: >MHC studies of the primary antiphospholipid syndrome and of antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 1996, 23:1173-1179.
17. Sebastiani GD, Galeazzi M, Morozzi G, Marcolongo R: The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies and lupus anticoagulant. Semin Arthritis Rheum 1996, 25:414-420.
18. Arnett FC, Olsen ML, Anderson KL, Reveille JD: Molecular analysis of major histocompatibility alleles associated with the lupus anticoagulant. J Clin Invest 1991, 87:1490-1495.
19. Vargas-Alarcon G, Granados J, Bekker C, Alcocer-Varela J, Alarcon-Segovia: Association of HLA DR5 (possibly DRB1-1201) with the primary antiphospholipid syndrome in Mexican patients. Arthritis Rheum 1995, 38:1340-1343.
20. Panzer S, Pabinger I, Gaswandtner ME, Moyr WR, Hutter D: Lupus anticoagulants: strong associations with the major histocompatibility complex class II and platelet antibodies. Br J Heamatol 1997, 98:342-345. An increased frequency of HLA-DQB1*06 alleles was demonstrated in patients with SLE and primary antiphospholipid syndrome, particularly in those with antiplatelet antibodies or a history of thromboembolic events.
21. Carliz AR, Atsumi T, Kondeatis E, Khamashta MA, Amengual O, Knights S, Vaughan RV, Lanchbury JS, Hughes GRV: Association of primary antiphospholipid syndrome and anti-beta 2 glycoprotein I antibodies with the HLA DRB1*1302 allele. Arthritis Rheum 1997, 40(suppl):S104.
22. Schur PH: Complement and systemic lupus erythematosus. In Dubois' Lupus Erythematosus. Edited by Wallace DR, Hahn BH. Baltimore: Williams & Wilkins; 1997:245-251.
23. Slingsby JH, Norsworthy P, Pearce G, Vaishnaw AK, Issler H, Morley BJ, Walport MJ: Homozygous hereditary C1q deficiency and systemic lupus erythematosus. Arthritis Rheum 1996, 39:663-670.
24. Arnett FC, Reveille JD: Genetics of systemic lupus erythematosus. Rheum Dis Clin North Am 1992, 18:865-892
25. Moulds JM, Reveille JD, Arnett FC: Structural polymorphisms of complement receptor 1 (CR1) in systemic lupus erythematosus (SLE) and normal controls of three ethnic groups. Clin Exp Immunol 1996, 105:302-305.
26. Sastry K, Herman G, Day L, Diegnan E, Bruns G, Morton CC, Ezekowitz RAB: The human mannose-binding protein gene: exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10. J Exp Med 1989, 170:1175-1189.
27. Sastry K, Ezekowitz RAB: Collectins: pattern recognition molecule involved in first line host defense. Curr Opin Immunol 1993, 5:59-65.
28. Lu J, Thile S, Wiedemann H, Timpl R, Reid KBM: Binding of the pentamer/hexamer forms of mannan-binding protein to zymosan activates the proenzyme C1rC1s2 complex of the classical complement pathway without involvement of C1 q. J Immunol 1990, 144:2287-2294.
29. Lipscombe RJ, Sumiya M, Hill AVS, Lau Y, Levinsky RJ, Summerfield JA, Turner MW: High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. Hum Mol Genet 1992, 1:709-715.
30. Lipscombe RJ, Sumiya M, Summerfield JA, Turner MW: Distinct physiochemical characteristics of human mannose binding protein expressed by individuals of differing genotypes. Immunology 1995, 85:660-667.
31. Summerfield JA, Ryder S, Sumiya M, Thursz M, Gorchein A, Monteil MA, Turner MW: Mannose binding protein gene mutations associated with unusual and severe infections in adults. Lancet 1995, 345:886-889.
32. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB: Glycosylation changes of IgG associated with rheumatoid arthritis can active complement via mannose-binding protein. Nat Med 1995 1:237-243.
33. Kohl LE, Atkinson JP: Autoimmune aspects of complement deficiency. Clin Aspects Autoimmun 1988, 2:8-20.
34. Davies EJ, Snowden N, Hillarby MC, Carthy D, Grennan DM, Thomson W, Ollier WER: Mannose-binding protein gene polymorphism in systemic lupus erythematosus. Arthritis Rheum 1995, 38:110-114.
35. Senaldi G, Davies ET, Pearkman M, Veragani D, Lu J, Reid KBM: Frequency of mannose-binding protein deficiency in patients with systemic lupus erythematosus. Arthritis Rheum 1995, 38:1713-1714.
36. Lau YL, Lau CS, Chan SY, Karlberg J, Turner MW: Mannose-binding protein in Chinese patients with systemic lupus erythematosus. Arthritis Rheum 1996, 39:706-708.
37. Sullivan KE, Wooten C, Goldman D, Petri M: Mannose-binding protein genetic polymorphisms in black patients with systemic lupus erythematosus. Arthritis Rheum 1996, 39:2046-2051.
38. Davies EJ, The LS, Ordi-Ros J, Snowden N, Hillarby MC, Hajeer A, Donn R, Perez-Pemen P, Villrdell-Tarres, Ollier WER: A dysfunctional allele of mannose-binding protein associates with systemic lupus erythematosus is a Spanish population. J Rheumatol 1997, 24:485-488. At least one dysfunctional allele of MBP, unable to activate complement, and a C4 null allele was present in a majority of Spanish SLE patients studied. This suggests that both genes may contribute to susceptibility in a additive manner.
39. Wilson AG, di Giovine F, Duff GW: Genetics of tumor necrosis factor-α in autoimmune, infectious and neoplastic diseases. J Inflamm 1995, 45:1-12.
40. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO: Hereditable major histocompatibility complex class II associated differences in production of tumor necrosis factor α. Proc Natl Acad Sci USA 1990, 87:1233-1237.
41. Studnicka-Benke, Steiner G, Petera P, Smolen JS: Tumor necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996, 35:1067-1074.
42. Hajeer AH, Worthington J, Davies EJ, Hillarby MC, Poulton K, Ollier WER: TNF microsatellite a2, b3 and d2 alleles are associated with systemic lupus erythematosus. Tissue Antigens 1997, 49:222-227. The frequency of TNF alleles, which belong to an extended HLA-DR3 haplotype and correlate with Raynaud's phenomenon and photosensitivity, was increased in SLE patients. TNF microsatellite allele associations are not independent of HLA but may be important in the expression of certain clinical features of SLE.
43. Sturfelt G, Hellmer G, Trudsson L: TNF microsatellites in systemic lupus erythematosus, a high frequency of the TNFabc 2-3-1 haplotype in multi-case SLE families. Lupus 1996, 5:618-622.
44. Danis VA, Millington M, Hyland V, Lawford R, Huang Q, Grennan: Increased frequency of the uncommon allele of a tumor necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers 1995, 12:127-133.
45. Wilson AG, Gordon C, di Giovine FS, De Vries N, van de Putte LB, Emery P, Duff GW: A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. Eur J Immunol 1994, 24:191-195.
46. D'Alfonso S, Colombo G, Della Bella S, Scorza R, Momigliano-Richardi P: Association between polymorphisms in the TNF region and systemic lupus erythematosus in the Italian population. Tissue Antigens 1996, 47:551-555. The authors determined which TNF allelic combinations occurred with certain extended HLA haplotypes. Some TNF alleles are found at higher frequencies in SLE patients, which probably reflected the primary HLA-DR3 haplotype association.
47. Rudwaliet M, Tikly M, Khamashta M, Gibson K, Klinke J, Hughes G, Wordsworth P: Interethnic differences in the association of tumor necrosis factor polymorphisms with systemic lupus erythematosus. J Rheumatol 1996, 32:1725-1728.
48. Suillivan KE, Wooten C, Schmeckpeper BJ, Goldman D, Petri MA: A promoter polymorphism of tumor necrosis factor a associated with systemic lupus erythematosus in African Americans. Arthritis Rheum 1997, 40:2207-2211. HLA-DR3 is not associated with SLE or linkage disequilibrium with TNF-2 in blacks. The frequency of the TNF-2 polymorphism was significantly higher in SLE patients compared with controls and is associated with increased risk for SLE in blacks.
49. Fong KY, Howe HS, Tin SKM, Boey ML, Feng PH: Polymorphism of the regulatory region of tumor necrosis factor alpha gene in patients with systemic lupus erythematosus. Ann Acad Med Singapore 1996, 25:90-93.
50. Chen J, Yen JH, Tsai WC, Wu CS, Chiang WW, Tsai JJ, Liu HW: The TNF2 allele does not contribute toward susceptibility to systemic lupus erythematosus. Immunol Lett 1997, 55:1-3.
51. Lu LY, Ding WZ, Fici D, Deulofeut R, Cheng HH, Cheu CC, Sung PK, Schur PH, Fraser PA: Molecular analysis of major histocompatibility complex allelic associations with systemic lupus erythematosus. Arthritis Rheum 1997, 40:1138-1145. HLA-DQB1*0507 and TNF-2 were associated with SLE in Taiwanese Chinese SLE patients. The TNF-2 association was independent of HLA-DR3 because DR3 was not increased in the SLE patients.
52. Tomita H, Hashimoto S, Yamagami K, Sawada S, Horie T: Restriction fragment length polymorphism (RFLP) analysis in the TNF gene of patients with systemic lupus erythematosus. Clin Exp Rheumatol 1993, 11:533-536.
53. Bertinotti MP, Hartung K, Diecher H, Messer G, Keller E, Weiss EJ, Albert ED: Polymorphism of the tumor necrosis factor beta gene in systemic lupus erythematosus: TNFB-MHC haplotypes. Immunogenetics 1993, 37:449-454.
54. Kim TG, Kim HY, Lee SH, Cho CS, Park SH, Choi HB, Han H, Kim DJ: Systemic lupus erythematosus with nephritis is strongly associated with TNFB*2 homozygotes in the Korean population. Hum Immunol 1996, 46:10-17.
55. Rascu A, Repp R, Westerdaal NAC, Kalden JR, van de Winkle JGJ: Clinical relevance of Fcγ receptor polymorphisms. Ann N Y Acad Sci 1997, 815:282-295.
56. Kimberly RP, Salmon JE, Edgerg J: Receptors for immunoglobulin G. Arthritis Rheum 1995, 38:306-314.
57. Diuts AJ, Bootsma H, Derksen RHWM, Spronk PE, Kater L, Kallenberg CGM, Capel PJA, Westerdaal NAC, Spierenburg GT, Gmelig-Myeling FHJ, van de Winkle JGJ: Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum 1995, 39:1832-1836.
58. Salmon JE, Millard S, Schacter LA, Arnett FC, Ginzler EM, Gourley MF, Ramsey-Goldman R, Peterson MGE, Kimberly RP: FcγRIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1995, 97:1348-1354.
59. Botto M, Theodoridis E, Thompson EM, Beynon HLC, Briggs D, Isenberg DA, Walport MJ, Davies KA: FcγIIa polymorphism in systemic lupus erythematosus (SLE): no association with disease. Clin Exp Immunol 1996, 104:264-268.
60. Enenkel B, Jung D, Frey J: Molecular basis of IgG Fc receptor defect in a patient with systemic lupus erythematosus. Eur J Immunol. 1991, 21:659-663.
61. Wainstin E, Edberg J, Csernol E, Sneller M, Hoffman G, Keystone E, Gross S, Salmon J, Kimberly R: FcγIIIb alleles predict renal dysfunction in Wegener's granulomatosis (WG). Arthritis Rheum 1996, 39(suppl):S210.
62. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, Salmon JE, Kimberly RP: A novel polymorphism of FcγIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997, 100:1059-1070. The authors report a novel polymorphism in the FcγIIIa gene that encodes high- and low-affinity isoforms. SLE patients have an underrepresentation of the high-affinity phenotype, and a strong association was observed with the low-binding phenotype of FcγIIIa, particularly in SLE patients with nephritis.
63. Clynes R, Dumitru C, Ravetch JV: Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998, 279:1052-1054. Using crossbreeding experiments, the authors created a lupus-prone mouse strain that lacks Fcγ receptor. These mice develop immune-complex deposition in the kidneys yet do not develop nephritis, suggesting that Fcγ receptors are necessary for autoimmune glomerulonephritis.
64. Horowitz DA, Stohl W, Gray JD: >T-lymphocytes, natural killer cells, cytokine and immune regulation. In Dubois' Lupus Erythematosus. Edited by Wallace DR. Hahn BH. Baltimore: Williams & Wilkins; 1997:155-194.
65. Linker-Israeli M, Wallance DJ, Prehn JL, Nand R, Li L, Klinenberg JR: A greater variability in the 3 flanking region of the IL-6 gene in patients with systemic lupus erythematosus (SLE). Autoimmunity 1996, 23:199-209.
66. Arend WP: lnterleukin-1 receptor antagonist: a new member of the interleukin-1 family. J Clin Invest 1991, 88:1445-1451.
67. Blakemore AIF, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW: Interleukin-1 receptor antagonist gene receptor polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 1994, 37:1380-1385.
68. Suzuki H, Matsui Y, Kashiwagi H: Interleukin-1 receptor antagonist gene polymorphism in Japanese patients with systemic lupus erythematosus. Arthritis Rheum 1997, 40:389-390. This study reports an association between a particular polymorphism in the IL-1Ra and SLE, particularly photosensitivity in Japanese patients. The same polymorphism has been implicated as a disease severity factor in white SLE patients.
69. Llorente L, Jou W, Levy Y, Richard-Patin Y, Wijdenes J, Alcocer-Varela J, Morel-Fourrier B, Brouet JC, Alarcon-Segovia D, Galanaud P, Emilie D: Role of interleukin-10 in the B-lymphocyte hyperactivity and autoantibody production in systemic lupus erythematosus. J Exp Med 1995, 181:839-844.
70. Hagiwara E, Gourley MF, Lee S, Klinman DM: Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10: interferon-γ-secreting cells in the peripheral blood. Arthritis Rheum, 1996, 39:379-385.
71. Kalechman Y, Gafte U, Da JP, Albeck M, Alarcon-Segovia D, Sredni B: Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101. J Immunol 1997, 159:2658-2667. In lupus-prone (NZB/NZW)F, mice, treatment with AS101, an immunomodulator that decreases IL-10 levels, rapidly lowered anti-dsDNA titers and reduced the ncidence of glomerulonephritis.
72. Eskdale J, Wordsworth P, Bowman S, Field M, Gallagher G: Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus. Tissue Antigens 1997, 49:635-639. This paper reports a significant difference in the frequency distribution of an IL-10 promoter microsatellite between SLE patients and ethnically matched controls. The presence of anti-extractable nuclear antigens antibodies was associated with a specific IL-10 promoter allele.
73. Kube D, Platzer C, von Knethen A, Straub H, Bohlen H, Hafner M, Tesch H: Isolation of the human interleukin 10 promoter: characterization of the promoter activity in Burkitt's lymphoma cell lines. Cytokine 1995, 7:1-7.
74. Llorente L, Richaud-Patin Y, Couderc J, Alarcon-Segovia D, Ruiz-Soto R, Alcocer-Castillejos N, Alcocer-Varela J, Granados J, Bahena S, Galanaud P, Emilie D: Dysregulation of IL-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum 1997, 40:1429-1435. Dysregulated IL-10 production was observed in a large proportion of healthy family members of SLE patients. IL-10 production was caused by a subpopulation of activated B lymphocytes and may play a role in the autoimmunity that is sometimes observed in these kindreds of SLE patients.
75. Tebib JG, Alcocer-Varela J, Alarcon-Segovia D, Schur P: Association between a T cell receptor RFLP and systemic lupus erythematosus. J Clin Invest 1990, 86:1961-1967.
76. Huang DF, Siminovitch K, Liu XY, Olee T, Olsen NJ, Berry C, Carson DA, Chen PP: Population and family studies of three disease-related polymorphic genes in systemic lupus erythematosus. J Clin Invest 1995, 95:1766-1772.
77. Huang Q, Morris D, Dunckley, Grennan D, Manolios N: Lack of linkage between antinuclear antibody or clinical features of systemic lupus erythematosus and TCRA/Vb loci in families of subjects with SLE. Lupus 1997, 6:527-532. This sibpair analysis of a large kindred of multiplex and simplex SLE families, that demonstrated no evidence of linkage between ANA positivity or SLE with the TCR-A and TCR-Vβ genes.
78. Kono DH, Theofilopoulos AN: Genetic contributions to SLE. J Autoimmun 1996, 9:437-452.
79. Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S, Harris AW: Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 1992, 88:8661-8665.
80. Vyse TJ, Kotzin BL: Genetic basis of systemic lupus erythematosus. Curr Opin Rheumatol 1996, 8:843-851.
81. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD: Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996, 98:1107-1113.
82. Huang QR, Morris D, Manolios N: Evaluation of the Bcl-2 gene as a susceptibility locus linked to the clinical expression of systemic lupus erythematosus. Rheumatol Int 1996, 16:121-124.
83. Lorenz HM, Grunke M, Hieronymous T, Hermann M, Kuhnel A, Manger B, Kalden JR: In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum 1997, 40:306-317. The authors isolated lymphocytes from patients with SLE, rheumatoid arthritis, and other connective tissue diseases and measured the percentage of apoptosis after activation. Although the expression of Fas protein was increased in SLE lymphocytes, mRNA levels of Fas, FasL, and bcl-2 did not differ between SLE and control cells. The authors suggest that increased Fas and bcl-2 protein expression may not be specific for SLE.
84. Rosenthal N, Schwartz RS: In search of perverse polymorphisms. N Engl J Med 1998, 338:122-124.
85. Tsao BP, Cantor RM, Kalunian KC, Chen CJ, Badsha H, Singh R, Wallace DJ, et al.: Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J Clin Invest 1997, 99:725-731. The authors studied a candidate region with homology to a mouse SLE susceptibility locus on human chromosome 1q. Sibpair analysis in three ethnic groups showed evidence of linkage in a region on 1q41-42, suggesting that this candidate region contains an SLE susceptibility locus.
86. Tsao BP, Cantor RM, Badsha H, Grossman JM, Klunian KC, Hartung K, Arnett FC, Wallace DJ, Hahn BH, Rotter JI: A susceptibility gene for SLE maps to a 5 cM region of chromosome 1q. Arthritis Rheum 1997, 40(suppl):S315.